Resources>Citations Database>A Novel Designed Anti–PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity

A Novel Designed Anti–PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity

Biointron 2024-11-18

Authors: Baocun Li, Shiyong Gong, Nianying Zhang, Beilei Shi, Zhou Lv, Yu Zhang, Naren Gaowa, Liqin Dong, Danqing Wu, Jianfu Wu, Fan Liu, Rui Zhang, Ramin Behzadigohar, Vinod Ganju, Chengbin Wu, Xuan Wu

Journal: Mol Cancer Ther 2024

PubMed ID: 39575565

DOI: https://doi.org/10.1158/1535-7163.MCT-24-0330

Products & Services: OX40 ECD wild-type (WT) and four mouse OX40 chimeras (each hOX40 CRD was replaced with its hOX40 counterpart) were expressed and purified by Biointron through transfection

Recommended Articles
MRNA Profiling Involved in Triggering of STAT1 with Regulatory Involvement of IRF7, PTPRF, and miR-145p in Patients Suffering from Gall Bladder Carcinoma
Nov 25, 2025
Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybrids for Drug Delivery

Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybri……

Aug 07, 2025
Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma

Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of ……

Aug 01, 2025
Inhibition of long-lived plasma cells, a critical role for Telitacicept treatment to systemic lupus erythematosus

Inhibition of long-lived plasma cells, a critical role for Telitacicept treatmen……

Jul 30, 2025

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.